These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29791027)

  • 1. Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications.
    Rudini N; Novello C; Destro A; Riboldi E; Donadon M; Viganò L; Morenghi E; Roncalli M; Di Tommaso L
    Histopathology; 2018 Oct; 73(4):601-611. PubMed ID: 29791027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution.
    Takeda H; Takai A; Kumagai K; Iguchi E; Arasawa S; Eso Y; Shimizu T; Ueda Y; Taura K; Uemoto S; Kita R; Haga H; Marusawa H; Fujimoto A; Seno H
    J Pathol; 2020 Dec; 252(4):398-410. PubMed ID: 32815153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
    Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
    J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
    J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
    Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
    Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice.
    Qiao Y; Xu M; Tao J; Che L; Cigliano A; Monga SP; Calvisi DF; Chen X
    BMC Cancer; 2018 Nov; 18(1):1093. PubMed ID: 30419856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
    Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
    Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
    Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
    World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple β-catenin mutations in hepatocellular lesions arising in Abernethy malformation.
    Sorkin T; Strautnieks S; Foskett P; Peddu P; Thompson RJ; Heaton N; Quaglia A
    Hum Pathol; 2016 Jul; 53():153-8. PubMed ID: 27038679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic analysis with the hierarchical cluster analysis strategy on the complex interaction of TERT and CTNNB1 somatic mutations in Vietnamese hepatocellular carcinoma patients.
    Thu Nguyen T; Van Tran K; Cam Ho T; Xuan Nguyen H; Trong Nguyen T
    Gene; 2024 Nov; 927():148646. PubMed ID: 38851365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant transformation of a β-catenin inflammatory adenoma due to an S45 β-catenin-activating mutation present 12 years before.
    Sempoux C; Bisig B; Couchy G; Balabaud C; Zucman-Rossi J; Bioulac-Sage P
    Hum Pathol; 2017 Apr; 62():122-125. PubMed ID: 27984126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics.
    Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Sanada J; Koda W; Minami T; Inoue D; Yoshida K; Yamashita T; Yamashita T; Kaneko S; Takamura H; Ohta T; Ikeda H; Nakanuma Y; Kita R; Gabata T
    Radiology; 2015 Jun; 275(3):708-17. PubMed ID: 25668519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characteristics of Wnt/β-catenin-deregulated hepatocellular carcinoma.
    Verma A; Bal M; Ramadwar M; Deodhar K; Patil P; Goel M
    Indian J Cancer; 2017; 54(4):634-639. PubMed ID: 30082549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver.
    Osada T; Sakamoto M; Nishibori H; Iwaya K; Matsuno Y; Muto T; Hirohashi S
    J Hepatol; 1997 Jun; 26(6):1266-73. PubMed ID: 9210613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
    Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
    Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.
    Ando S; Shibahara J; Hayashi A; Fukayama M
    Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
    Campani C; Imbeaud S; Couchy G; Ziol M; Hirsch TZ; Rebouissou S; Noblet B; Nahon P; Hormigos K; Sidali S; Seror O; Taly V; Ganne Carrie N; Laurent-Puig P; Zucman-Rossi J; Nault JC
    Gut; 2024 Oct; 73(11):1870-1882. PubMed ID: 39054058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.